Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030183 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
A Phase 2 study, sponsored by Ra Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03030183 is a Phase 2 study that has completed, run by Ra Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT03030183, a Phase 2 study, has completed, sponsored by Ra Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
Interventions
- DRUG Zilucoplan (RA101495)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030183
The ClinicalTrials.gov registry entry for NCT03030183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ra Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zilucoplan (RA101495) is the first listed.
NCT03030183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030183 about?
NCT03030183 is a clinical study titled "Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab". The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
What is the current status of trial NCT03030183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-17. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT03030183?
The interventions under investigation include: Zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT03030183?
This trial is sponsored by Ra Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.